RituximabRecent, repeatedEvidence- NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Rituximab” · registered Oct 2026
- NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Rituximab” · registered Sep 2026
- NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Rituximab” · registered Jul 2026
- NCT07189065 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Rituximab” · registered Sep 2025
- NCT06929624 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Rituximab Injection” · registered Apr 2025
| Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others | 1113 studies | 1419 studies | background 37 · comparator 17 |
CyclophosphamideRecent, repeatedEvidence- NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Cyclophosphamide” · registered Sep 2026
- NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Cyclophosphamid” · registered Jul 2026
- NCT07124936 · huadong medicine · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2025
- NCT07035379 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 · live · background · “Cyclophosphamide” · registered Jun 2025
- NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Cyclophosphamide” · registered Mar 2025
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 1011 studies | 1314 studies | background 32 |
DoxorubicinRecent, repeatedEvidence- NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Doxorubicin” · registered Jul 2026
- NCT07124936 · huadong medicine · Phase 2 · live · background · “Doxorubicin” · registered Aug 2025
- NCT07035379 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 · live · background · “Doxorubicin” · registered Jun 2025
- NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Doxorubicin” · registered Mar 2025
- NCT06717347 · Merck & Co., Inc · Phase 3 · live · background · “Doxorubicin” · registered Dec 2024
| Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed | 67 studies | 89 studies | background 22 |
LenalidomideRecent, repeatedEvidence- NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Lenalidomide” · registered Oct 2026
- NCT07189065 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Lenalidomide” · registered Sep 2025
- NCT05660967 · Genmab · Phase 2 · background · “Lenalidomide” · registered Nov 2022
- NCT05626322 · Pfizer · Phase 2 · background · “Lenalidomide” · registered Nov 2022
- NCT05328102 · Xencor, Inc. · Phase 2 · background · “Lenalidomide” · registered Apr 2022
| Bristol-Myers Squibb61% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 4 generics authorized | 67 studies | 57 studies | comparator 2 · background 12 |
GemcitabineRecent, repeatedEvidence- NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Gemcitabine Hydrochloride” · registered Sep 2026
- NCT07124936 · huadong medicine · Phase 2 · live · background · “Gemcitabine” · registered Aug 2025
- NCT06929624 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Apr 2025
- NCT06806033 · Hoffmann-La Roche · Phase 2 · live · background · “Gemcitabine” · registered Jan 2025
- NCT06792253 · BeBetter Med Inc · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Jan 2025
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 55 studies | 810 studies | background 13 · comparator 6 |
PrednisoneRecent, repeatedPhase 4 trial recordedEvidence- NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Prednisone” · registered Jul 2026
- NCT07124936 · huadong medicine · Phase 2 · live · background · “Prednisone” · registered Aug 2025
- NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Prednisone” · registered Mar 2025
- NCT06717347 · Merck & Co., Inc · Phase 3 · live · background · “Prednisone” · registered Dec 2024
- NCT06091865 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Prednisone/Prednisolone” · registered Oct 2023
| Johnson & Johnson11% of its industry studies | 56 studies | 78 studies | background 21 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Sep 2026
- NCT07124936 · huadong medicine · Phase 2 · live · background · “Oxaliplatin” · registered Aug 2025
- NCT06929624 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Oxaliplatin Injection” · registered Apr 2025
- NCT06806033 · Hoffmann-La Roche · Phase 2 · live · background · “Oxaliplatin” · registered Jan 2025
- NCT06792253 · BeBetter Med Inc · Phase 3 · live · comparator · “Oxaliplatin Injection” · registered Jan 2025
| Sanofi35% of its industry studies | 55 studies | 79 studies | background 12 · comparator 4 |
VincristineRecent, repeatedEvidence- NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Vincristine Sulfate” · registered Sep 2026
- NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Vincristine” · registered Jul 2026
- NCT06717347 · Merck & Co., Inc · Phase 3 · live · comparator · “Vincristine” · registered Dec 2024
- NCT06091865 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Vincristine” · registered Oct 2023
- NCT04824092 · Incyte Corporation · Phase 3 · live · background · “Vincristine” · registered Mar 2021
| Bristol-Myers Squibb9% of its industry studies | 44 studies | 66 studies | comparator 2 · background 15 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT06093841 · Shanghai Ming Ju Biotechnology Co., Ltd. · Phase 2 · live · background · “Fludarabine” · registered Oct 2023
- NCT05972720 · CARGO Therapeutics · Phase 2 · background · “Fludarabine (Conditional therapy)” · registered Jul 2023
- NCT05826535 · Lyell Immunopharma, Inc. · Phase 2 · live · background · “Fludarabine” · registered Mar 2023
- NCT04836507 · Curocell Inc. · Phase 2 · live · background · “Fludarabine” · registered Apr 2021
- NCT04792489 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Fludarabine” · registered Feb 2021
| Beijing Biotech18% of its industry studies | 33 studies | 44 studies | background 10 |
PrednisoloneRecent, repeatedPhase 4 trial recordedEvidence- NCT07035379 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 · live · background · “Prednisolone” · registered Jun 2025
- NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Prednisolone” · registered Mar 2025
- NCT06717347 · Merck & Co., Inc · Phase 3 · live · background · “Prednisolone” · registered Dec 2024
- NCT06091865 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Prednisone/Prednisolone” · registered Oct 2023
- NCT01897571 · Ipsen · Phase 2 · background · “Prednisolone” · registered Jun 2013
| Sanofi15% of its industry studies | 34 studies | 34 studies | background 6 |
bendamustineRecent, repeatedEvidence- NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Bendamustine” · registered Oct 2026
- NCT07189065 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Bendamustine” · registered Sep 2025
- NCT04792489 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Bendamustine” · registered Feb 2021
- NCT04663347 · Genmab · Phase 2 · live · background · “rituximab and bendamustine” · registered Oct 2020
- NCT04607772 · Karyopharm Therapeutics Inc · Phase 2 · background · “Bendamustine” · registered Oct 2020
| Teva Pharmaceutical Industries, Ltd.25% of its industry studiesUS: off-patent, 3 generics marketed | 22 studies | 44 studies | comparator 3 · background 12 |
polatuzumab vedotinRecent, repeatedEvidence- NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Polatuzumab vedotin” · registered Oct 2026
- NCT06890884 · Merck & Co., Inc · Phase 2 · live · comparator · “Polatuzumab vedotin” · registered Mar 2025
- NCT05283720 · Genmab · Phase 2 · live · background · “Polatuzumab Vedotin” · registered Mar 2022
- NCT04607772 · Karyopharm Therapeutics Inc · Phase 2 · background · “Polatuzumab Vedotin” · registered Oct 2020
| Hoffmann-La Roche92% of its industry studiesUS: Hoffmann-La Roche (FDA 2019)EU: Hoffmann-La Roche (EMA 2020) | 23 studies | 23 studies | comparator 2 · background 2 |
tafasitamabRecent, repeatedEvidence- NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Tafasitamab” · registered Oct 2026
- NCT05328102 · Xencor, Inc. · Phase 2 · background · “Tafasitamab” · registered Apr 2022
- NCT04607772 · Karyopharm Therapeutics Inc · Phase 2 · background · “Tafasitamab” · registered Oct 2020
| Incyte Corporation47% of its industry studiesUS: Novartis (FDA 2020)EU: Incyte Corporation (EMA 2021) | 22 studies | 11 study | comparator 1 · background 2 |